Article Details

Insilico Medicine Nominates Preclinical Candidate Targeting KAT6A for ER+/HER2

Retrieved on: 2022-12-27 17:35:33

Tags for this article:

Click the tags to see associated articles and topics

Insilico Medicine Nominates Preclinical Candidate Targeting KAT6A for ER+/HER2. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/12/27/2579968/0/en/Insilico-Medicine-Nominates-Preclinical-Candidate-Targeting-KAT6A-for-ER-HER2-Breast-Cancer-Therapy-with-End-to-End-AI-Engine.html

Excerpt

New York, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug.

Article found on: www.globenewswire.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up